Bolt Biotherapeutics . Stock News

Bolt Biotherapeutics Inc (BOLT) shares closed today 10.5% higher than it did at the end of yesterday. The stock is currently down 84.6% year-to-date, down 84.6% over the past 12 months, and down 84.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $5.15 and as low as $4.31 this week.Shares closed 88.5% below its 52-week high and 24.7% above its 52-week low.Trading volume this week was 4.4% lower than the 10-day average and 62.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 587.6% The company's stock price performance over the past 12 months lags the peer average by 577.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

At least one of the three could be in store for better news in the future.

REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021.

SVB Leerink reaffirmed their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report report published on Thursday morning, Price Targets.com reports. A number of other research analysts have also weighed in on BOLT. Zacks Investment Research raised Bolt Biotherapeutics from a sell rating to a hold rating in a research report on […] The post SVB Leerink Reaffirms Buy Rating for Bolt Biotherapeutics (NASDAQ:BOLT) appeared first on ETF Daily News .

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective increased by Stifel Nicolaus from $19.00 to $34.00 in a research report report published on Monday morning, The Fly reports. Stifel Nicolaus currently has a buy rating on the stock. The analysts noted that the move was a valuation call. A number of other equities analysts also recently []

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective lifted by Stifel Nicolaus from $19.00 to $34.00 in a research note issued to investors on Monday, The Fly reports. They currently have a buy rating on the stock. The analysts noted that the move was a valuation call. Several other equities research analysts have also commented on []

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

Bolt Biotherapeutics Inc (NASDAQ: BOLT ) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR7/8 agonist. The data were shared at the European Society for Medical Oncology Immuno-Oncology (ESMO Full story available on Benzinga.com

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) compris

California State Teachers Retirement System decreased its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 16.6% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 15,960 shares of the companys stock after selling 3,172 shares during the quarter. California State Teachers Retirement Systems holdings in Bolt Biotherapeutics were worth $247,000 as of its most []

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated to a TLR7/8 agonist with a non-cleavable linker.